(2R,3R,4S,5R)-2-(6-Amino-2-((3-phenylpropyl)amino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol | 124499-05-4

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: (2R,3R,4S,5R)-2-(6-Amino-2-((3-phenylpropyl)amino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
• 英文别名: (2R,3R,4S,5R)-2-[6-amino-2-(3-phenylpropylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 124499-05-4
• 化学式: C₁₉H₂₄N₆O₄
• 分子量: 400.437
• InChiKey: KNGDTUPYRQLCDN-SCFUHWHPSA-N

物化性质

• 沸点：
  768.1±70.0 °C(Predicted)
• 密度：
  1.60±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  152
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  6-氯鸟嘌呤核苷 在 copper(l) iodide 、 氨 、 碘 、 亚硝酸异戊酯 作用下， 以 四氢呋喃 、 乙二醇甲醚 为溶剂， 反应 42.5h， 生成 (2R,3R,4S,5R)-2-(6-Amino-2-((3-phenylpropyl)amino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
  参考文献：
  名称：

  Adenosine Analogues as Inhibitors of Trypanosoma brucei Phosphoglycerate Kinase:  Elucidation of a Novel Binding Mode for a 2-Amino-N⁶-Substituted Adenosine

  摘要：

  As part of a project aimed at structure-based design of adenosine analogues as drugs against African trypanosomiasis, N-6-, 2-amino-N-6-, and N-2-substituted adenosine analogues were synthesized and tested to establish structure-activity relationships for inhibiting Trypanosoma brucei glycosomal phosphoglycerate kinase (PGK), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and glycerol-3-phosphate dehydrogenase (GPDH). Evaluation of X-ray structures of parasite PGK, GAPDH, and GPDH complexed with their adenosyl-bearing substrates led us to generate a series of adenosine analogues which would target all three enzymes simultaneously. There was a modest preference by PGK for NG-substituted analogues bearing the 2-amino group. The best compound in this series, 2-amino-N-6-[2 "-(p-hydroxyphenyl)ethyl]adenosine (46b), displayed a 23-fold improvement over adenosine with an IC50 of 130 muM. 2-[[2 "-(p-Hydroxyphenyl)ethyl]amino]adenosine (46c) was a weak inhibitor of T. brucei PGK with an IC50 of 500 muM. To explore the potential of an additive effect that having the N-6 and N-2 substitutions in one molecule might provide, the best ligands from the two series were incorporated into N-6,N-2-disubstituted adenosine analogues to yield N-6-(2 " -phenylethyl)-2-[(2 " -phenylethyl)amino]adenosine (69) as a 30 muM inhibitor of T. brucei PGK which is 100-fold more potent than the adenosine template. In contrast, these series gave no compounds that inhibited parasitic GAPDH or GPDH more than 10-20% when tested at 1.0 mM. A 3.0 Angstrom X-ray structure of a T, brucei PGK/46b complex revealed a binding mode in which the nucleoside analogue was flipped and the ribosyl moiety adopted a syn conformation as compared with the previously determined binding mode of ADP. Molecular docking experiments using QXP and SAS program suites reproduced this "flipped and rotated" binding mode.

  DOI：

  10.1021/jm000287a

文献信息

• Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines
  作者：John E. Francis、Randy L. Webb、Geetha R. Ghai、Alan J. Hutchison、Michael A. Moskal、Reynalda DeJesus、Rina Yokoyama、Stephen L. Rovinski、Nicolina Contardo

  DOI：10.1021/jm00112a035

  日期：1991.8

  with the moderately A2 receptor selective adenosine agonist 2-anilinoadenosine (CV-1808). High selectivity combined with significant affinity at the A2 receptor in rat membranes was observed for those amines bearing a two-carbon chain to which was attached an aryl, heteroaryl, or alicyclic moiety. 2-(2-Phenethylamino)adenosine (3d), a 14-fold A2 selective compound, was modified by introduction of a variety

  制备了多种2-取代的氨基腺苷与中度A2受体选择性腺苷激动剂2-苯胺基腺苷（CV-1808）进行比较。对于那些带有连接了芳基，杂芳基或脂环族部分的双碳链的胺，观察到了高选择性以及对大鼠膜上A2受体的显着亲和力。通过在苯环和侧链中引入各种取代基，对14倍的A2选择性化合物2-（2-苯乙氨基）腺苷（3d）进行了修饰。这些变化中的一些导致改善的A2亲和力和增加的选择性。用环己烯基取代苯基部分产生210倍选择性激动剂3ag（CGS 22989），而环己基类似物3af（CGS 22492）在A2位点具有530倍选择性。
• Certain 2-substituted adenosine derivatives
  申请人：CIBA-GEIGY AG

  公开号：EP0323807A2

  公开（公告）日：1989-07-12

  Disclosed are 2-substituted adenosine derivatives of the formula wherein R represents a substituted amino grouping as defined in the specification, which are therapeutically effective adenosine-2 (A-2) agonists. They are prepared by methods known per se.

  公开了式中的 2-取代腺苷衍生物 其中 R 代表说明书中定义的取代氨基，是治疗有效的腺苷-2（A-2）激动剂。它们是通过本身已知的方法制备的。
• 2-SUBSTITUTED ADENOSINES WITH A-2 RECEPTOR AFFINITY
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0662975A1

  公开（公告）日：1995-07-19
• [EN] 2-SUBSTITUTED ADENOSINES WITH A-2 RECEPTOR AFFINITY<br/>[FR] ADENOSINES SUBSTITUEES EN POSITION 2 PRESENTANT UNE AFFINITE AVEC LE RECEPTEUR A-2
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：WO1994007905A1

  公开（公告）日：1994-04-14

  (EN) Adenosine analogues which act selectively at adenosine receptors and which act in general as adenosine agonists are disclosed. From $i(in vitro) studies it is known that specific physiological effects can be distinguished as a result of this selectivity and that adenosine receptor activity $i(in vitro) correlates with adenosine receptor activity $i(in vivo). Pharmaceutical preparations of the subject compounds can be prepared on the basis of the selective binding activity of the compounds disclosed herein which will enhance certain physiological effects while minimizing others, such as decreasing blood pressure without decreasing heart rate.(FR) Cette invention concerne des analogues d'adénosine qui agissent sélectivement au niveau de récepteurs d'adénosine et qui agissent généralement comme des agonistes d'adénosine. On sait, grâce aux recherches effectuées $i(in vitro) qu'on peut distinguer des effets physiologiques spécifiques comme résultat de cette sélectivité et que l'activité du récepteur d'adénosine $i(in vitro) est en corrélation avec l'activité du récepteur d'adénosine $i(in vivo). On peut préparer des préparations pharmaceutiques des composés de cette invention en se fondant sur l'activité de liaison sélective des composés décrits lesquels stimulent certains effets physiologiques tout en mimisant d'autres par exemple en faisant baisser la pression sanguine sans faire baisser la fréquence cardiaque.
• Adenosine Analogues as Inhibitors of <i>Trypanosoma </i><i>b</i><i>rucei </i>Phosphoglycerate Kinase:  Elucidation of a Novel Binding Mode for a 2-Amino-N⁶-Substituted Adenosine
  作者：Jerome C. Bressi、Jungwoo Choe、Melinda T. Hough、Frederick S. Buckner、Wesley C. Van Voorhis、Christophe L. M. J. Verlinde、Wim G. J. Hol、Michael H. Gelb

  DOI：10.1021/jm000287a

  日期：2000.11.1

  As part of a project aimed at structure-based design of adenosine analogues as drugs against African trypanosomiasis, N-6-, 2-amino-N-6-, and N-2-substituted adenosine analogues were synthesized and tested to establish structure-activity relationships for inhibiting Trypanosoma brucei glycosomal phosphoglycerate kinase (PGK), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and glycerol-3-phosphate dehydrogenase (GPDH). Evaluation of X-ray structures of parasite PGK, GAPDH, and GPDH complexed with their adenosyl-bearing substrates led us to generate a series of adenosine analogues which would target all three enzymes simultaneously. There was a modest preference by PGK for NG-substituted analogues bearing the 2-amino group. The best compound in this series, 2-amino-N-6-[2 "-(p-hydroxyphenyl)ethyl]adenosine (46b), displayed a 23-fold improvement over adenosine with an IC50 of 130 muM. 2-[[2 "-(p-Hydroxyphenyl)ethyl]amino]adenosine (46c) was a weak inhibitor of T. brucei PGK with an IC50 of 500 muM. To explore the potential of an additive effect that having the N-6 and N-2 substitutions in one molecule might provide, the best ligands from the two series were incorporated into N-6,N-2-disubstituted adenosine analogues to yield N-6-(2 " -phenylethyl)-2-[(2 " -phenylethyl)amino]adenosine (69) as a 30 muM inhibitor of T. brucei PGK which is 100-fold more potent than the adenosine template. In contrast, these series gave no compounds that inhibited parasitic GAPDH or GPDH more than 10-20% when tested at 1.0 mM. A 3.0 Angstrom X-ray structure of a T, brucei PGK/46b complex revealed a binding mode in which the nucleoside analogue was flipped and the ribosyl moiety adopted a syn conformation as compared with the previously determined binding mode of ADP. Molecular docking experiments using QXP and SAS program suites reproduced this "flipped and rotated" binding mode.